Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2000

View Archived Issues

Discovery of new generation of ribozymes and compound with potent activity against HER-2 oncogene

TAP and IPF PharmaCeuticals enter research collaboration

Basel Institute for Immunology to become a center for medical genomics with Roche support

AVI BioPharma and collaborators offer key findings for polycystic kidney disease drug development

Japanese launch of Dovonex ointment imminent

NovoLog granted FDA approval for treatment of diabetes mellitus

Interneuron updates clinical and regulatory plans for trospium

Neurocrine Biosciences advances obesity and diabetes research program

Bioniche uncovers new class of agents with anticancer activity

Rat studies demonstrate feasibility of AAV-TNFR:Fc gene therapy in rheumatoid arthritis

New tryptase inhibitor effective against allergic airways inflammation in animal model

ICN-10776 reported at Immunology 2000 to induce Th2 cytokine bias

Data presented this week on antiproliferative activity and mechanism of action of CT-3

Inflazyme receives investment; advances development programs

Preliminary pharmacological profile of NMI-377 presented at ASBMB/ASPET 2000

NO donors revealed as novel therapeutic agents for female sexual dysfunction

Calyx's new tyrphostin compound exerts both antidiabetic and antiinflammatory effects

GenVec receives payment for BioByPass milestone

New thiazole derivatives for inhibiting cell adhesion

New mGluR1 antagonists claimed by Lilly for migraine and CNS disorders

Alcon discovers utility of glutamate antagonists for retinal disorders

Rizatriptan + rofecoxib claimed by Merck for use in migraine

More effective, better tolerated combinations for migraine

Orally active and selective COX-2 inhibitors described by Abbott

Takeda patents new series of somatostatin receptor-modulating aromatic amines

Vanadium complexes with hypoglycemic and antiproliferative effects

Cytokine production inhibitors developed by SB for inflammatory disorders

Pfizer presents new ketolides and use for infections and cancer

Cortex receives funding to test CX-516 in patients with mild cognitive impairment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...